Chemical macrocyclization of peptides fused to antibody Fc fragments

Bioconjugate Chemistry

Volumn 23, Issue 9, 2012, Pages 1856-1863

  Angelini, Alessandro ^a,b   Diderich, Philippe ^a   Morales Sanfrutos, Julia ^a   Thurnheer, Sarah ^a   Hacker, David ^a   Menin, Laure ^a   Heinis, Christian ^a  

^a INSTITUTE OF CHEMICAL SCIENCES AND ENGINEERING   (Switzerland)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; CHEMICAL REACTIONS;

CLEAN REACTIONS; CYSTEINE RESIDUES; FUSION PROTEINS; HALF LIVES; MACRO-CYCLIZATION; OPTIMISATIONS; PEPTIDE FUSION; PEPTIDE MOIETY; SERUM PROTEINS; SIDE PRODUCTS;

PEPTIDES;

CYSTEINE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; PLASMINOGEN ACTIVATOR INHIBITOR; UK 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL REACTION; CONJUGATION; CONTROLLED STUDY; CYCLIZATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE;

MUS;

EID: 84866396578     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300184m     Document Type: Article

References (25)

1. Heinis, C., Rutherford, T., Freund, S., and Winter, G. (2009) Phage-encoded combinatorial chemical libraries based on bicyclic peptides Nat. Chem. Biol. 5, 502-7
2. Angelini, A., Cendron, L., Chen, S., Touati, J., Winter, G., Zanotti, G., and Heinis, C. (2012) Bicyclic peptide inhibitor reveals large contact interface with a protease target ACS Chem. Biol. 7, 817-21
3. Baeriswyl, V., Rapley, H., Stace, C., Pollaro, L., Teufel, D., Walker, E., Chen, S., Winter, G., Tite, J., and Heinis, C. Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologs while sparing paralogous proteases. ChemMedChem 2012, not supplied.
4. Timmerman, P., Beld, J., Puijk, W. C., and Meloen, R. H. (2005) Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces ChemBioChem 6, 821-4 (Pubitemid 40873739)
5. Matzke, G. R., Zhanel, G. G., and Guay, D. R. (1986) Clinical pharmacokinetics of vancomycin Clinical Pharmacokinetics 11, 257-82 (Pubitemid 16050520)
6. Tan, A. C., Russel, F. G., Thien, T., and Benraad, T. J. (1993) Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics Clinical Pharmacokinetics 24, 28-45 (Pubitemid 23042128)
7. Cockshott, I. D. (2000) Clinical pharmacokinetics of goserelin Clinical Pharmacokinetics 39, 27-48 (Pubitemid 30468203)
8. Pollaro, L. and Heinis, C. (2010) Strategies to prolong the plasma residence time of peptide drugs MedChemComm 1, 319-324
9. Kontermann, R. E. (2011) Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22, 868-76
10. Huang, C. (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology Curr. Opin. Biotechnol. 20, 692-9
11. McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., and Carter, P. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng., Des. Sel. 19, 299-307 (Pubitemid 43999640)
12. Carter, P. J. and Senter, P. D. (2008) Antibody-drug conjugates for cancer therapy Cancer j. 14, 154-69
13. Senter, P. D. (2009) Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13, 235-44
14. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-37
15. Lyon, R. P., Meyer, D. L., Setter, J. R., and Senter, P. D. (2012) Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues Methods Enzymol. 502, 123-38
16. Andreasen, P. A., Egelund, R., and Petersen, H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis Cell. Mol. Life Sci. 57, 25-40 (Pubitemid 30105328)
17. Ridgway, J. B., Presta, L. G., and Carter, P. (1996) Knobs-into-holes engineering of antibody CH3 domains for heavy chain heterodimerization Protein Eng. 9, 617-21 (Pubitemid 26241639)
18. Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., Sweet, H., Foltz, I. N., Wittekind, M., and Yan, W. (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG J. Biol. Chem. 285, 19637-46
19. Bitonti, A. J. and Dumont, J. A. (2006) Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway Adv. Drug Delivery Rev. 58, 1106-18 (Pubitemid 44709269)
20. Dumont, J. A., Low, S. C., Peters, R. T., and Bitonti, A. J. (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics BioDrugs 20, 151-60 (Pubitemid 43845335)
21. Mezo, A. R., McDonnell, K. A., Low, S. C., Song, J., Reidy, T. J., Lu, Q., Amari, J. V., Hoehn, T., Peters, R. T., Dumont, J., and Bitonti, A. J. (2012) Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats Bioconjugate Chem. 23, 518-26
22. Gupta, R. and Brunak, S. (2002) Prediction of glycosylation across the human proteome and the correlation to protein function Pacific Symposium on Biocomputing 310-22
23. Yoo, E. M. and Morrison, S. L. (2005) IgA: an immune glycoprotein Clin. Immunol. 116, 3-10 (Pubitemid 40733577)
24. Kim, J. K., Firan, M., Radu, C. G., Kim, C. H., Ghetie, V., and Ward, E. S. (1999) Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn Eur. J. Immunol. 29, 2819-25 (Pubitemid 30099006)
25. Ying, T., Chen, W., Gong, R., Feng, Y., and Dimitrov, D. S. (2012) Soluble Monomeric IgG1 Fc J. Biol. Chem. 287, 19399-408